Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048695 | 0.83 | POLB (0.47) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL1492674 | 0.77 | AKR1C1 (0.49) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL16751921 | 0.77 | POLB (0.44) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL22004708 | 0.76 | POLB (0.35) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL23972281 | 0.75 | POLB (0.34) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL31226931 | 0.74 | HDAC4 (0.53) | POLBHCAR2ITGA4ITGB7 | |
| SCHEMBL18698028 | 0.74 | OPRM1 (0.45) | HPGDALDH1A1GAA | |
| SCHEMBL25348541 | 0.72 | KDM4E (0.46) | POLBHCAR2KDM4EITGA4ITGB7 | |
| SCHEMBL31226690 | 0.72 | ITGA4 (0.47) | POLBHCAR2KDM4EITGA4ITGB7 | |
| SCHEMBL23164255 | 0.72 | ALOX5 (0.39) | POLBHCAR2KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CHAMOIN SYLVIE (FR) | 2013-11-07 | — | — | US | disclosed |
| US-8519142-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| EP-2429995-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | POLB 3029/4885HCAR2 1635/4885KDM4E 993/4885 |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | POLB 3029/4885HCAR2 1635/4885KDM4E 993/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | POLB 1741/4885HCAR2 906/4885KDM4E 4213/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | POLB 3029/4885HCAR2 1635/4885KDM4E 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.